<DOC>
	<DOCNO>NCT01407562</DOCNO>
	<brief_summary>This open label , dose escalation study determine safety tolerability maximum tolerate dose pazopanib combine weekly paclitaxel carboplatin patient advance solid tumor .</brief_summary>
	<brief_title>Study Pazopanib , Paclitaxel , Carboplatin Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>This open label , dose escalation study determine maximum tolerate dose ( MTD ) pazopanib combine weekly paclitaxel carboplatin patient advance solid tumor . There dose expansion cohort thirty patient assess detailed pharmacokinetics assess signal activity patient solid tumor portion breast cancer triple negative ( ER-negative , PR-negative , HER2-negative ) .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Confirmed diagnosis solid malignancy advance disease relapse , refractory standard therapy , standard therapy , patient opts receive standard therapy . At recommended phase II dose level , triplenegative breast cancer define ERnegative , PRnegative , HER2negative , enrol another 10 patient solid malignancy would benefit paclitaxel carboplatinbased regimen , also enrol . Male female â‰¥ 18 year age Able swallow retain oral medication Major surgery within last 28 day cytotoxic chemotherapy , biologic therapy , investigational agent , radiotherapy within last 21 day . Patients complete therapy mitomycin C nitrosurea wait 42 day . More 3 prior line cytotoxic chemotherapy metastatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>